רופילק 300

Țară: Israel

Limbă: ebraică

Sursă: Ministry of Health

Cumpara asta acum

Ingredient activ:

ANTI-D IMMUNOGLOBULINS

Disponibil de la:

CSL BEHRING LTD., ISRAEL

Codul ATC:

J06BB01

Forma farmaceutică:

תמיסה להזרקה

Compoziție:

ANTI-D IMMUNOGLOBULINS 150 MCG/ML

Calea de administrare:

תוך-שרירי, תוך-ורידי

Tip de prescriptie medicala:

מרשם נדרש

Produs de:

CSL BEHRING AG, SWITZERLAND

Grupul Terapeutică:

ANTI-D (RH) IMMUNOGLOBULIN

Zonă Terapeutică:

ANTI-D (RH) IMMUNOGLOBULIN

Indicații terapeutice:

Prophylaxis of Rh (D) immunisation in Rh (D)-negative women: Anti-D immune globulin is administered for the prevention of Rh (D) immunization if it has been demonstrated or if it is suspected that fetal erythrocytes have entered the circulation of the mother. Treatment is not necessary when it is assured that the child or the father are Rh (D)- negative. Criteria for a rhesus-incompatible pregnancy and the administration of anti-D immune globulin are : a) the mother is Rh (D) -negative b) the child is either Rh (D)-positive Rh (D)weak - positive or its rhesus type is not known. Routine antepartum prophylaxis : To prevent Rh (D) immunisation due to spontaneous fetomaternal haemorrhage (FMH) during the last trimester of pregnancy. Postpartum prophylaxis To prevent Rh (D) immunisation of the Rh (D)-negative mother following delivery of a Rh (D)-positive child. Complications of pregnancy: Interventions during pregnancy such as invasive prenatal diagnosis (e.g. amniocentesis chorionic villus sampling fetal blood s

Data de autorizare:

2023-02-28

Documente în alte limbi

Caracteristicilor produsului Caracteristicilor produsului engleză 13-09-2023
Raport public de evaluare Raport public de evaluare engleză 08-06-2023

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor